Targets › CYP46A1
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Apr 2028.
P450 monooxygenase that plays a major role in cholesterol homeostasis in the brain. Primarily catalyzes the hydroxylation (with S stereochemistry) at C-24 of cholesterol side chain, triggering cholesterol diffusion out of neurons and its further degradation. (UniProt, Q9Y6A2)
Open in Phaseline: the race on CYP46A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AskBio France, SAS, a subsidiary of AskBio | AB-1001 (AAVrh10.CAG.hCYP46A1) AAV-mediated gene delivery of human cholesterol 24-hydroxylase (CYP46A1) | CYP46A1 | Phase 1 | Huntington Disease | Apr 2028 |
Huntington Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.